Evidence mapPaperPMID 22690846Full record

ReviewExpert opinion on drug safety2012

Drug-induced hypoglycaemia in type 2 diabetes.

Berit Inkster, Nicola N Zammitt, Brian M Frier

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Expert opinion on drug safety, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02925559 (Effect of Anti-diabetic Drugs on Glycemic Variability. A Comparison Between Gliclazide MR), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02925559 phase4completedstarted 2016, after this paper: background citation

Effect of Anti-diabetic Drugs on Glycemic Variability. A Comparison Between Gliclazide MR (Modified Release) and Dapagliflozin on Glycemic Variability Measured by Continuous Glucose Monitoring (CGM) in Patients With Uncontrolled Type 2 Diabetes

Ran2016Enrolled135Registered outcomes9Posted comparisons0ConditionsDiabetes Mellitus, Type 2Armsdapagliflozin, Gliclazide MR
Open the trial in the graph
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Dementia in Diabetes: The Role of Hypoglycemia.International journal of molecular sciences · 2023
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.Diabetes, metabolic syndrome and obesity : targets and therapy · 2017 · on this map
    Review
  16. The suppressive effect ofFood science and biotechnology · 2017
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Berit InksterRoyal Infirmary of Edinburgh, Department of Diabetes, 51 Little France Crescent, Edinburgh, EH16 4SA, UK.
Nicola N Zammitt
Brian M Frier
Edinburgh Royal Infirmary · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHypoglycaemia is a side effect caused by some therapies for type 2 diabetes, which can cause physical, social and psychological harm. Hypoglycaemia also prevents attainment of treatment goals and satisfactory glycaemic control. AREAS COVERED: The risk of hypoglycaemia associated with commonly prescribed therapies, including metformin, sulphonylureas, dipeptidyl peptidase-4 enzyme (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonists and thiazolidinediones, is reviewed in this paper (insulin-induced hypoglycaemia is not included). Other medications that are frequently co-prescribed in type 2 diabetes are also discussed, including anti-hypertensive drugs, antibiotics and fibrates, along with various important patient-related risk factors. EXPERT OPINION: Hypoglycaemia is a common and potentially dangerous side effect of some medications used for type 2 diabetes. The risk of hypoglycaemia should always be considered when selecting and implementing a therapy, with a focus on the individual. Future research into new therapies should measure the frequency of hypoglycaemia prospectively and accurately. Hypoglycaemia has been shown to be a potentially life-threatening metabolic stress; therefore therapies that effectively manage diabetes without the risk of hypoglycaemia are likely to be favoured in the future.

Indexed as

AdamantaneAngiotensin-Converting Enzyme InhibitorsDiabetes Mellitus, Type 2DipeptidesExenatideHumansHypoglycemiaHypoglycemic AgentsMetforminPeptidesPharmacogeneticsPioglitazoneSulfonylurea CompoundsThiazolidinedionesVenomsAdamantaneAngiotensin-Converting Enzyme InhibitorsDipeptidesExenatideHypoglycemic AgentsMetforminPeptidesPioglitazonesaxagliptinSulfonylurea CompoundsThiazolidinedionesVenoms

Identifiers

PMID22690846
OpenAlexW2118409853

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.